Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 5/20 | 0.61 |
| ▸ | GLA | P06280 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740177 | 0.90 | ALDH1A1 (0.75) | KDM4EALDH1A1LMNAPOLBGLA | |
| SCHEMBL2624739 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1LMNAPOLBRAB9A | |
| SCHEMBL13470853 | 0.84 | POLB (0.56) | KDM4EALDH1A1LMNAPOLBGLA | |
| SCHEMBL2740281 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1LMNAPOLBGLA | |
| SCHEMBL2624510 | 0.83 | MAPT (0.57) | KDM4EALDH1A1LMNAPOLBGLA | |
| SCHEMBL2624432 | 0.82 | TP53 (0.69) | KDM4EALDH1A1LMNAPOLBHTT | |
| SCHEMBL2740239 | 0.81 | SIRT1 (0.56) | KDM4EALDH1A1LMNAPOLBGLA | |
| SCHEMBL7284460 | 0.81 | KDM4E (0.58) | KDM4EALDH1A1LMNAPOLBGLA | |
| SCHEMBL7291378 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1LMNAPOLBGLA | |
| SCHEMBL2740240 | 0.80 | ALDH1A1 (0.70) | KDM4EALDH1A1LMNAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-21 | — | — | US | disclosed |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-21 | — | — | US | disclosed |
| US-9040521-B2 | Methods and compositions for modulating tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040521-B2 | Methods and compositions for modulating tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-05-26 | — | — | US | disclosed |
| US-8748464-B2 | Use of SIRT1 activators or inhibitors to modulate an immune response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | disclosed |
| EP-1910362-B1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | KDM4E 750/4885ALDH1A1 2181/4885LMNA 4750/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | KDM4E 1227/4885ALDH1A1 1700/4885LMNA 3283/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | KDM4E 540/4885ALDH1A1 844/4885LMNA 3132/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | KDM4E 1399/4885ALDH1A1 1903/4885LMNA 2572/4885 |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | KDM4E 1388/4885ALDH1A1 1331/4885LMNA 3473/4885 |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | MAPT, NEFM, PSEN2 | KDM4E 3152/4885ALDH1A1 3746/4885LMNA 761/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | KDM4E 1388/4885ALDH1A1 1331/4885LMNA 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.